compounsing semaglutide ending 🚨 FDA Moves to Permanently Shut Down Compounded GLP-1s The FDA is taking steps to eliminate large-scale compounding of GLP-1 medications like and tirzepatide, signaling a major shift in how these GLP-1 Shortage = Over -

- : 48 ,

Though the medication was originally developed as a diabetes drug, its been shown to be effective for a myriad of conditions, like polycystic ovarian syndrome and migraines

So why would adding glucagon receptor activation to a GLP-1 agonist be beneficial in research models

Tirzepatide is an ideal weight loss medication for adults with obesity or overweight individuals who haven't had success with diet and exercise alone

Gastritis is a common condition that affects many people

Compounded GLP-1 medications are prescribed only when a licensed healthcare provider determines, based on an individual patients medical needs, that an FDA-approved drug is not appropriate or that a clinically significant difference exists, such as dosage form, strength, or excipient composition